Aclaris Therapeutics, Inc. Common Stock (NASDAQ: ACRS) last traded at $3.60, down 6.01% on the session. The quote above updates while this page is open; the figures below are drawn from Aclaris Therapeutics, Inc. Common Stock’s own filings and are restated only when a new one is published.
Aclaris Therapeutics, Inc. Common Stock trades on NASDAQ under the ticker ACRS. Its market capitalisation is $529.92 million.
Valuation measures for Aclaris Therapeutics, Inc. Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $529.92M |
|---|---|
| Enterprise value | $565.86M |
| Price / sales | 64.47 |
| Price / book | 4.25 |
| Beta | 0.45 |
Trailing-twelve-month figures tagged in Aclaris Therapeutics, Inc. Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $8.22M |
|---|---|
| Net income (TTM) | -$75.74M |
| EPS (TTM) | -$0.580 |
| Gross margin | 79.52% |
| Operating margin | -1050.16% |
| Return on equity | -60.79% |
| Cash | $19.17M |
Range and volume for ACRS over the past 52 weeks.
| 52-week high | $6.60 |
|---|---|
| 52-week low | $1.74 |
| Volume | 3.43M |
| Average volume | 2.66M |
| Previous close | $3.83 |
Invest a chosen dollar amount in Aclaris Therapeutics, Inc. Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell ACRS.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.